Based on the presence and retention of FcγRIIIa-expressing effector cells in HER2+ breast cancer and TNBC, including residual disease, and their association with clinical outcomes, we hypothesized that Fc-engineering mAbs with enhanced FcγRIIIa affinity could enhance antitumor mechanisms. This evidence concerns the gene FCGR3A and breast carcinoma.